Fischer Medical Ventures Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares that were previously rejected or returned due to various deficiencies. The initiative demonstrates the company's commitment to facilitating smooth share transfer processes for its investors.

Special Window Details

The company has established a dedicated timeframe for addressing previously unsuccessful share transfer requests. This special window provides shareholders with an opportunity to rectify and resubmit their transfer documentation.

Regulatory Compliance

The special window initiative follows regulatory guidelines and demonstrates Fischer Medical Ventures' adherence to SEBI requirements. The company has taken this step in compliance with specific regulatory directives aimed at facilitating share transfer processes.

Public Notification

Fischer Medical Ventures has ensured widespread awareness of this initiative through strategic newspaper publications. The company published advertisements in both English and regional language publications to reach a diverse shareholder base.

The newspaper advertisements were published on March 12, 2026 in:

• Financial Express (English daily with electronic edition)
• Vishalandra (Telugu daily with electronic edition)

Shareholder Action Required

Shareholders who have previously faced issues with physical share transfers are advised to take advantage of this special window. The company has provided clear guidance on the submission process and documentation requirements.

Key actions for affected shareholders:

• Review previously rejected or returned transfer requests
• Gather required documentation as specified by the company
• Submit complete documentation to the company's Registrar and Share Transfer Agent
• Ensure submission within the specified window period

Corporate Communication

The announcement was formally communicated to stock exchanges as part of the company's disclosure obligations. Fischer Medical Ventures submitted the notification to both BSE Limited and National Stock Exchange of India Limited on March 12, 2026, ensuring transparency and regulatory compliance in its communication with stakeholders.

Fischer medical ventures Limited has announced a strategic investment through its subsidiary in the Indonesian healthcare market. The company's wholly owned subsidiary, FMV Global Innovations Pte Limited, has acquired a 75% stake in PT Fischer Pariko Medical Ventures, marking the company's expansion into Southeast Asian markets.

Investment Structure and Details

The investment was formalized through a regulatory filing dated March 03, 2026, submitted to both BSE Limited and the National Stock Exchange of India under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The transaction establishes PT Fischer Pariko Medical Ventures as a related party to Fischer Medical Ventures Limited through the subsidiary investment structure.

Target Company Profile

PT Fischer Pariko Medical Ventures operates in the healthcare sector, focusing on wholesale of medical, professional, scientific and precision equipment. The Indonesian company was incorporated on October 14, 2024, making it a recently established entity in the healthcare distribution space.

Regulatory Compliance and Structure

The investment transaction falls within the related party framework, as FMV Global Innovations Pte Limited is a 100% subsidiary of Fischer Medical Ventures Limited. The company has confirmed that no governmental or regulatory approvals were required for this acquisition, and no direct cash consideration was involved in the transaction.

The filing indicates that the objects and effects of acquisition, indicative time period for completion, and nature of consideration were marked as not applicable, suggesting this was a straightforward equity participation in the newly incorporated Indonesian entity. The investment aligns with Fischer Medical Ventures' core healthcare business operations, representing a natural extension of the company's existing medical equipment and healthcare services portfolio into international markets.